Publication date: Dec 17, 2024
To evaluate the treatment strategies that dictate the host susceptibility to secondary bacterial infections during coronavirus disease 2019 (COVID-19). Setting and Participants: This nested case-control study was conducted in three general hospitals in China between December 1, 2022, to March 1, 2023. A total of 456 confirmed COVID-19 patients matched 1:2 (152 cases and 304 controls) based on age, sex, disease severity and age-adjusted Charlson Comorbidity Index (aCCI) using Propensity-Score Matching (PSM) were included. Association of secondary bacterial infections with treatment strategies including the supportive measures, antiviral, and antibacterial therapies. Conditional logistic regression analyses demonstrated that among categorical variables, use of antibiotics, antivirals, intravenous injection of human immunoglobulin, glucocorticoids or anticoagulants were not associated with the risk of secondary bacterial infections in the COVID-19 patients. The use of supplemental oxygen by either low (Odds ratio (OR): 0. 18, P
Concepts | Keywords |
---|---|
Antibiotics | Antibiotics |
China | Antivirals |
December | Coronavirus disease 2019 |
Host | Pneumonia |
Semantics
Type | Source | Name |
---|---|---|
drug | DRUGBANK | Oxygen |
disease | MESH | Bacterial Infections |
disease | IDO | host |
disease | IDO | susceptibility |
disease | MESH | coronavirus disease 2019 |
disease | MESH | Comorbidity |
disease | MESH | Pneumonia |